Hepatocyte

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University

Retrieved on: 
Tuesday, October 25, 2022
Method, News, Asialoglycoprotein receptor, Mode, Spinocerebellar ataxia, U.S. Securities and Exchange Commission, Therapy, Nature Chemical Biology, ATACS, Multiple myeloma, Degenerative disease, Myostatin, NYSE, Neuroscience, Drug development, Hepatocyte, Immunology, Professor, Financial condition report, Result, Security (finance), Lists of diseases, PROTAC, Technology, Cancer, Private Securities Litigation Reform Act, NEW, Conversation, Marketing, Epilepsy, Analysis, Neuropathic pain, Patent, Safety, Tic disorder, Protein, TRPM3, TPD, Proteolysis, FDA, WO, Degradation, Risk, Fine chemical, Pharmaceutical industry, Yale University

Biohaven advances development of its extracellular target degrader platform technology (MoDEs) for therapies across a variety of diseases including neuroscience, immunology and oncology

Key Points: 
  • Biohaven advances development of its extracellular target degrader platform technology (MoDEs) for therapies across a variety of diseases including neuroscience, immunology and oncology
    Through its continued collaboration with Yale University in the laboratory of Professor David Spiegel and Biohaven Labs, Biohaven has made further innovations in this ground-breaking technology with new patent applications covering additional targets and functionality
    In-licensed from Yale University in 2021, the MoDE platform is based on patent applications filed by Yale in 2018 and 2019
    NEW HAVEN, Conn., Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN; "Biohaven") today announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.
  • In 2021, Biohaven entered into a worldwide, exclusive license agreement to develop and commercialize the MoDE platform based on ground-breaking research conducted in the laboratory of Professor David Spiegel at Yale University.
  • Through the novel approach, Professor Spiegel demonstrated the modularity of the MoDE technology by synthesizing bifunctional molecules that induce the degradation of both antibody and pro-inflammatory cytokine proteins.
  • Since entering into the license agreement with Yale in 2021, Yale has filed more than eight additional patent applications covering this technology.

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Retrieved on: 
Monday, October 10, 2022
Institute of Liver and Biliary Sciences, Lung, NOAEL, Disease, U.S. Securities and Exchange Commission, Therapy, Liver disease, Degenerative disease, Edu, Annual report, Liver injury, Retina, SCID, Hepatocyte, RATS, Hepatitis, Research, Tissue, Regeneration, Security (finance), Cell proliferation, Eye, Soft tissue injury, SC, Inflammation, Nasdaq, Coronavirus, United European Gastroenterology, Mouse, Probability, Trial of the century, Human, Cornea, Alcoholic hepatitis, CEO, Liver, Skin, GLOBE, Ulcerative colitis, Fibrosis, Forward-looking statement, Inflammatory bowel disease, Homeostasis, No-observed-adverse-effect level, GLP, Toxicology, COVID-19, Pancreas, Dietary supplement, Pharmaceutical industry, WNT

Phase 1 clinical trials of our SZN-1326 and SZN-043 programs were initiated in May and June, respectively, and are ongoing.

Key Points: 
  • Phase 1 clinical trials of our SZN-1326 and SZN-043 programs were initiated in May and June, respectively, and are ongoing.
  • Surrozen believes that the transient, self-limited hepatocyte proliferation induced by SZN-043, is likely controlled by negative feedback loops responsible for regulation of cell proliferation and liver homeostasis.
  • SZN-043-related changes were considered non-adverse, limited to clinical chemistry and changes in organ weight and demonstrated evidence of recovery in most cases.
  • Surrozen is a clinical-stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway.

Metabolism-Dependent Cytotoxicity Assay (MDCA) for the Evaluation of the DILI Potential of Drug Candidates, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 4, 2022
GSH, Evaluation, Toxicity, Food, Doctor of Philosophy, Hepatotoxicity, Drug development, Pharmacology, Industry, Immortalised cell line, Glutathione, Hepatocyte, MDC, HEK293, Enzyme, Mitochondrial outer membrane permeabilization, Disulfiram-like drug, Toxicology, MDCA, Pharmaceutical industry

TORONTO , Oct. 4, 2022  /PRNewswire-PRWeb/ -- The metabolic activation and detoxification pathways of drug candidates is an important aspect of drug development. This information can be applied towards structural design to minimize toxicological liability of drug candidates, selection of animal species for preclinical evaluation of human toxicity, identification of at-risk populations based on metabolic activation and detoxification capacity and identification of environmental factors that may exacerbate drug toxicity via their induction of metabolic activating pathways and inhibition of detoxification pathways. An in vitro cytotoxicity assay can help enable this process.

Key Points: 
  • Attendees will learn the basis of developing the metabolism-dependent cytotoxicity assay (MDCA) and the utility of the MDCA.
  • The featured speaker will discuss plans to develop the MDC Index for comparative analysis to known drug-induced liver injury (DILI) drugs.
  • TORONTO, Oct. 4, 2022 /PRNewswire-PRWeb/ -- The metabolic activation and detoxification pathways of drug candidates is an important aspect of drug development.
  • For more information, or to register for this event, visit Metabolism-Dependent Cytotoxicity Assay (MDCA) for the Evaluation of the DILI Potential of Drug Candidates .

Global Single-cell Genome Sequencing Market Report (2022 to 2027) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Biotechnology, Genetics, Health, Cancer, Nephron, Hepatocyte, Granulocyte, MGI, Transcriptome, Neuron, Software, Technology, Intelligence, Industry, WHO, PCR, Infection, COVID-19, PerkinElmer, Growth, Laboratory, Single cell, DNA, RNA-Seq, HIVE, Mobile phone

The market segment's growth is boosted by the launch of products in the market.

Key Points: 
  • The market segment's growth is boosted by the launch of products in the market.
  • For instance, in June 2020, Stilla Technologies launched one of the world's first six-color digital PCR instruments named 'the six-color Prism'.
  • This system can be used widely in oncology, infectious disease, gene therapy, disease monitoring, and food testing.
  • Thus, due to the such factors, the studied market is expected to grow significantly during the forecast period.

Hepatitis Drugs Global Market Report 2022: Featuring Gilead, F Hoffmann-La Roche, Johnson & Johnson, Merck & GlaxoSmithKline PLC - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Health, Pharmaceutical, Hepatitis, Hepatocyte, Gilead Sciences, World Health Organization, Liver, WHO, Discovery and development of NS5A inhibitors, Asia-Pacific, Growth, HIV, Infection, NTCP, MYR, Acquisition, Interferon-alpha/beta receptor, Gilead, Route of administration, Injection, Thrombopoiesis, Nasal administration, Vaccine, Pharmaceutical industry

The "Hepatitis Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepatitis Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The increasing number of cases of different types of hepatitis is significantly driving the growth of the hepatitis drugs market.
  • Various types of hepatitis need different drugs for treatment and this increases the demand for hepatitis drugs.

BioIVT Announces Global eCommerce Collaboration With Charles River Laboratories Avian Vaccine Services

Retrieved on: 
Monday, October 3, 2022
Vaccine, Doctor of Philosophy, Marketing, Hepatocyte, Research, Precision medicine, Drug discovery, Blood, Twitter, Multimedia, Product, CRL, View, Product marketing, Fraction, Egg, Cell, Science, SPF, Quality control, Pharmacokinetics, Tissue, Virology, Online shopping

WESTBURY, N.Y., Oct. 3, 2022 /PRNewswire/ -- BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the addition of Avian products supporting vaccine manufacturing and virus research to the BioIVT Digital Portal through a global collaboration with the Avian Vaccine Services division of Charles River Laboratories International, Inc. (CRL). This agreement will benefit the research, diagnostic and manufacturing communities by leveraging the BioIVT Digital Portal to provide quick and easy access to high-quality specific-pathogen-free (SPF) eggs and related laboratory products such as virus antigens and antisera, and cells.  

Key Points: 
  • Charles River Avian products, which are used for virus research and to produce veterinary and human vaccines, are now available through the BioIVT Digital Portal
    WESTBURY, N.Y., Oct. 3, 2022 /PRNewswire/ --BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the addition of Avian products supporting vaccine manufacturing and virus research to the BioIVT Digital Portal through a global collaboration with the Avian Vaccine Services division of Charles River Laboratories International, Inc. (CRL).
  • The addition of the CRL Avian products will enable vaccine focused researchers to quickly access these products."
  • With the ease of interacting with the BioIVT Digital Portal, combined with our quality and expertise, we feel that this global collaboration will further support the research, diagnostic and vaccine manufacturing communities," said Debra Tosto, Executive Director, Avian Vaccine Services, Charles River.
  • Further, Charles River avian laboratory scientists continue to develop novel products to support the growing needs of vaccine manufacturing, diagnostics, and virology research.

e-therapeutics: Fundraise of £13.5 million

Retrieved on: 
Friday, September 30, 2022
Computational biology, Health, AIM, Time, Gene silencing, M&G, RNA interference, Sirna, NASH, Company, Growth, Investment, Subscription business model, IP, Nordisk, Biology, Liver, Platform, ETX, RNA, Medicine, Hepatocyte, Drug discovery, Galapagos NV, Pharmaceutical industry, Medical imaging, News

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

Key Points: 
  • Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:
    "I am pleased to announce the fundraise of 13.5 million and excited by the prospect of being able to accelerate the development of our in-house RNAi pipeline through enhanced investment in our therapeutic programmes, hepatocyte datasets and computational capabilities.
  • This successful fundraise underlines ETX's position at the intersection of computational approaches to drug discovery and genetic medicine, using RNA interference as our drug modality of choice.
  • We are grateful for the support of our shareholders and look forward to delivering value from our platform technologies."
  • The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

e-therapeutics: Fundraise of £13.5 million

Retrieved on: 
Friday, September 30, 2022
Computational biology, Health, AIM, Time, Gene silencing, M&G, RNA interference, Sirna, NASH, Company, Growth, Investment, Subscription business model, IP, Nordisk, Biology, Liver, Platform, ETX, RNA, First Fleet-class ferry, Medicine, Hepatocyte, Drug discovery, Galapagos NV, Pharmaceutical industry, Medical imaging, News

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

Key Points: 
  • Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:
    "I am pleased to announce the fundraise of 13.5 million and excited by the prospect of being able to accelerate the development of our in-house RNAi pipeline through enhanced investment in our therapeutic programmes, hepatocyte datasets and computational capabilities.
  • This successful fundraise underlines ETX's position at the intersection of computational approaches to drug discovery and genetic medicine, using RNA interference as our drug modality of choice.
  • We are grateful for the support of our shareholders and look forward to delivering value from our platform technologies."
  • The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection

Retrieved on: 
Thursday, September 22, 2022
Adult, Half-life, Safety, COVID-19, Sirna, Risk, Virus, Blood, ALT, U.S. Securities and Exchange Commission, HBsAg, Week, Coinfection, Viremia, Liver cancer, Private Securities Litigation Reform Act, Hepatitis B, HBV, Forward-looking statement, Alanine transaminase, Patient, Clinical trial, Drug development, Disease, Hepatitis B virus, Technology, HIV, Therapeutic index, Viral hepatitis, RNA, Research, GLOBE, Hepatocyte, HDV, Superinfection, Mortality, Immune system, Monoclonality, Infection, Death, Hepatocellular carcinoma, Vaccine, Pharmaceutical industry

SAN FRANCISCO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection alongside hepatitis B virus (HBV). HDV infection, the most aggressive form of viral hepatitis, increases the risk of poor outcomes, including liver cancer and death, compared with HBV alone.

Key Points: 
  • VIR-2218 and VIR-3434 are currently being evaluated for the treatment of HBV in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial.
  • Chronic hepatitis D virus (HDV) infection occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV).
  • Chronic hepatitis B virus (HBV) infection remains an urgent global public health challenge associated with significant morbidity and mortality.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and hepatitis D viruses, influenza A and human immunodeficiency virus.

BioIVT Launches GMP-grade VivoSTART Leukopaks for Cell and Gene Therapy Manufacturing

Retrieved on: 
Tuesday, September 20, 2022
VP, Precision medicine, Twitter, FDA, Blood, Quality, Cell, Serum, CFR, Fraction, Mesa, Good manufacturing practice, Tissue, Science, AB, Research, Pharmacokinetics, Hepatocyte, Multimedia, Drug discovery, GMP, View, Vaccine

WESTBURY, N.Y., Sept. 20, 2022 /PRNewswire/ -- BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its Good Manufacturing Practice (GMP-) grade VivoSTART™ leukopaks. Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies.

Key Points: 
  • Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies.
  • "This GMP-grade leukopak product introduction underscores BioIVT's commitment to being a high quality, global immune cell provider," said BioIVT CEO Dr. Richard Haigh.
  • With the VivoSTART leukopak launch, our customers can now transition seamlessly from research to manufacturing without compromising product integrity."
  • GMP-compliant VivoSTART leukopaks will serve as the ideal starting material for allogeneic ex vivo cell therapies and other advanced therapeutic applications.